RT Journal Article
SR Electronic
T1 Heterologous vaccination strategy for containing COVID-19 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.17.21257134
DO 10.1101/2021.05.17.21257134
A1 Lin, Ang
A1 Liu, JingJing
A1 Ma, Xiaopin
A1 Zhao, Fanfan
A1 Yu, Bo
A1 He, Jiaxin
A1 Shen, Mingyun
A1 Huang, Lei
A1 Tang, Hongming
A1 Jiang, Erpeng
A1 Wang, Yue
A1 Cui, Pingfang
A1 Zhang, Yujian
A1 Yao, Weiguo
A1 Zhang, Aihua
A1 Wang, Youchun
A1 Li, Yuhua
A1 Huang, Weijin
A1 Li, Qihan
A1 Liu, Zhongmin
A1 Li, Hangwen
YR 2021
UL http://medrxiv.org/content/early/2021/05/23/2021.05.17.21257134.abstract
AB An unequitable vaccine allocation and continuously emerging SARS-CoV-2 variants pose challenges to contain the pandemic, which underscores the need for licensing more vaccine candidates, increasing manufacturing capacity and implementing better immunization strategy. Here, we report data from a proof-of-concept investigation in two healthy individuals who received two doses of inactivated whole-virus COVID-19 vaccines, followed by a single heterologous boost vaccination after 7 months with an mRNA vaccine candidate (LPP-Spike-mRNA) developed by Stemirna Therapeutics. Following the boost, Spike-specific antibody (Ab), memory B cell and T cell responses were significantly increased. These findings indicate that a heterologous immunization strategy combining inactivated and mRNA vaccines can generate robust vaccine responses and therefore provide a rational and effective vaccination regimen.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialchinese clinical trial registry:ChiCTR2100046504Funding StatementThe study was supported by the National Key Research and Development Program of China (2020YFC0860300, to H.L), Shanghai Pujiang Talent Program (2020PJD068, to A.L), Shanghai Scientific Development Project (20431900300, to H.L) and internal funds from Stemirna Therapeutics, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the local ethical committee at Tongji University East Hospital, Shanghai, China. File number. EC.D(BG).016.03.1All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author.